Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. 483
  6. /
  7. RX South DBA RX3 Compounding Pharmacy LLC
483
•RX South DBA RX3 Compounding Pharmacy LLC•April 18, 2016

RX South DBA RX3 Compounding Pharmacy LLC – FDA 483, Apr 18, 2016

Record Details

An FDA inspection of RX South DBA RX3 Compounding Pharmacy, LLC, a producer of sterile drug products, was conducted from April 11-18, 2016. The inspection revealed multiple significant deviations from regulatory standards for manufacturing sterile drugs.

Key deficiencies included inadequate aseptic processing controls, such as brown stains on HEPA filters and rusty support structures in clean areas. Cleaning and disinfection procedures were found lacking, with no sporicidal disinfectants used in critical ISO 5 and ISO 7 classified areas. A major concern was the absence of adequate validation for sterilization processes, including for glycerin injectable and the depyrogenation of glassware, and media fills that did not simulate challenging conditions.

Environmental monitoring was also cited as insufficient, with viable and non-viable particulate monitoring not performed daily, and personnel monitoring being infrequent. Additionally, pressure differential gauges were uncalibrated, and certain pressure differentials were undocumented. The firm also lacked a written program to assess drug product stability, failing to test sterility, endotoxin, and potency throughout product shelf lives. Lastly, improper protective apparel was observed, with a technician exposing skin during aseptic processing.

These observations highlight multiple failures to adhere to current Good Manufacturing Practices for sterile drug production. RX South DBA RX3 Compounding Pharmacy, LLC is expected to implement comprehensive corrective and preventive actions to ensure product quality and sterility, and to achieve full compliance with FDA regulations.

Company
RX South DBA RX3 Compounding Pharmacy LLC
Inspection date
April 18, 2016
Product type
Drugs
Office
Baltimore District Office
People
  • Stacie A. Woods (Account Director)
  • Linda F. Murphy (SVP Consulting & Operations)
  • Haijing Hu (Director)
View Company Profile

ID · 69e7f373-3c66-416e-a2f6-eeee5b8289b6

Violation Codes4
FD&C Act 801(a)(3)21 CFR 331(c)21 CFR 21021 CFR 211

Full citation text and observation details available on the Dashboard.

Other documents for RX South DBA RX3 Compounding Pharmacy LLC
  • STATE_REFERRAL_LETTER - 2016-04-14April 14, 2016
  • WARNING_LETTER - 2014-02-21February 21, 2014
  • 483 - 2014-02-21February 21, 2014
  • 483 - 2012-12-14December 14, 2012

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore RX South DBA RX3 Compounding Pharmacy LLC
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.